Skip to content

A clinical study to assess the efficacy of a newer variety of an endoscopic device for diagnosing bile duct cancer

A randomized controlled study to assess diagnostic yield for malignant biliary strictures with newer variety of biliary brush

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/11/006332
Enrollment
52
Registered
2015-11-02
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients presenting to the gastroenterology department with features of cholestatic jaundice and clinical diagnosis of cholangiocarcinoma or stricture in common bile duct.

Interventions

Intervention1: 9 Fr wire-guided cytology brush (Infinity sampling device, US Endoscopy).: It has a combination of soft and stiff bristles for better tissue acquisition. Length of brush is 29 mm. Dia

Sponsors

Andhra Medical College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Biochemical evidence of cholestasis a.Increase of Alkaline Phosphatase greater than three times the upper normal limit And / or b.Serum direct bilirubin greater than 2.0 mg per dl OR 2.Extra hepatic bile duct stricture without discrete mass on Computer Tomography (CT) or Magnetic Resonance Imaging (MRI)or Magnetic resonance Cholangio Pancreatography (MRCP). AND 3.Documented extra hepatic biliary stricture during the Endoscopic Retrograde Cholangio Pancreatography (ERCP)

Exclusion criteria

Exclusion criteria: 1.Patients unwilling to participate in the trial 2.Inability to undergo standard ERCP (post surgical anatomy, other contraindications for ERCP) 3.No clinical suspicion for malignancy 4.CT or MRI scan showing an associated mass 5.Pregnancy, lactation 6.Children less than 12 yrs of age and adults greater than 90 years of age (both exclusive) 7.Endoscopically visible peri- ampullary tumor 8.Strictures not permitting the passage of guide wire or biliary brush 9.Previous brushing or placement of biliary stent. 10.Co- morbid conditons like chronic pancreatitis, Ampullary neoplasm, Carcinoma pancreas, Carcinoma Gall bladder,Hepatocellular carcinoma, metastatic disease with extrabiliary or unknown primary tumour, benign hepatic masses 11.Any ERCP evidence of bile duct compression 12.Postoperative, traumatic and idiopathic biliary strictures.

Design outcomes

Primary

MeasureTime frame
To identify the sensitivity and applicability of a newer cytology brush for tissue sampling of biliary strictures. The sensitivity, specificity, positive predictive value and negative predictive value will be calculated for both the randomized groups. Analysis will be done based on percentages, chi square test and other relevant tests of significance. Timepoint: Each patient will be followed up after the procedure and at the end of six months after randomization

Secondary

MeasureTime frame
To compare the percentage of patients diagnosed with malignant biliary stricture between newer and older variety of biliary btushTimepoint: The pathology report after the procedure is performed will be studied for this outcome

Countries

India

Contacts

Public ContactPalakurthy Murali Krishna

Andhra Medical College

muralikrishna63@yahoo.com9032032000

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026